Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etymemazine
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Intramuscular (veterinary Use)
01
Overview
Etymemazine is a phenothiazine derivative classified as an antipsychotic, antihistamine, and anticholinergic agent. It is structurally related to cyamemazine and methotrimeprazine. Etymemazine acts primarily as a histamine H1 receptor antagonist, conferring sedative and neuroleptic properties. It has been used experimentally in the treatment of dementia and also has veterinary applications. Its mechanism of action involves antagonism at histamine H1 receptors, with additional likely activity at dopamine receptors (as typical for phenothiazines), contributing to its antipsychotic effects[2][4][7].
- Other names
- ethylisobutrazineetymemazine [INN]ethotrimeprazine
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on etymemazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etymemazine.